Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of ILB-202 in Healthy Participants
NCT05843799Phase 1Completed
- Sponsor
- ILIAS Biologics
- Start
- May 2023
- Primary completion
- Oct 2023
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acute kidney injury (AKI) comparing ILB-202 with Placebo (2 arms). Primary endpoints: Incidence, severity and relationship to study treatment of Adverse Events, Concomitant medication usage and 1 more. Started May 2023; status: completed.
02
Drugs
ILB-202
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT05843799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05843799.